Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 91

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 5
Chunk 91
---
ITEM 5 OPERATING AND FINANCIAL REVIEW AND PROSPECTS
A. Operating Results
Overview
We are an international biotechnology company with a pipeline of novel antibody-based products and product candidates designed to address unmet medical needs and improve treatment outcomes for patients with cancer and other serious diseases. Our goal in building our pipeline is to bring medicines to market ourselves in geographic areas where we believe we will be able to maximize their value. 
Our current priorities are the late-stage programs epcoritamab, Rina-S and acasunlimab. Epcoritamab, marketed as EPKINLY in the US and Japan and TEPKINLY outside of those territories, is being developed and commercialized in collaboration with AbbVie. Epcoritamab is the first and only bispecific antibody approved in the US and Europe to treat both R/R DLBCL and R/R FL. It is also approved in Japan for R/R DLBCL. Rina-S and acasunlimab are wholly owned by Genmab and entered Phase III clinical development in 2024. 
Our full pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and ADCs. We currently have 12 proprietary products in total, including programs where we retain 50% of product rights in collaboration with partners, or product candidates in active clinical development. These also include our first commercial product, tisotumab vedotin, marketed as Tivdak. This is being developed and commercialized in collaboration with Pfizer. In 2024, Tivdak was granted full approval by the FDA for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is 

76

the first and only FDA approved ADC in this indication. In addition to our marketed products and clinical product candidates, we have multiple in-house and partnered pre-clinical programs.
To develop and deliver novel therapies to patients, we have formed strategic collaborations with biotechnology and pharmaceutical companies. We selectively enter into collaborations with other biotechnology and pharmaceutical companies that build our network in the biotechnology space and give us access to complementary technologies or products that move us closer to achieving our vision and fulfilling our core purpose. In addition to our own pipeline of product candidates, our innovation and proprietary technology are applied in the pipelines of third-party companies. These companies are running clinical development programs with antibodies created by us or created